Endocrine Abstracts

JOINT2098

This study investigates a novel niosome-encapsulated quercetin delivery system for enhanced thyroid cancer therapy, exploring its potential to minimize thyroid surgery. Quercetin, a promising anti-cancer flavonoid, suffers from poor bioavailability. Nevertheless, some previous studies proved its efficiency in thyroid cancer treatment. Niosomes offer a potential solution by improving drug delivery. Quercetin-loaded niosomes were fabricated using thin film hydration and characterized for size, morphology, stability, and release profile. Dynamic Light Scattering (DLS) showed a uniform particle size of ~70 nm indicating the successful formation of nanosized vesicles suitable for cellular uptake. Scanning Electron Microscopy (SEM) confirmed spherical morphology and Zeta potential indicated a stable formulation. Stability studies demonstrated the niosomes’ integrity over a period of time, proving their suitability for drug delivery applications. in vitro release profiles were evaluated at neutral and acidic pH. Sustained quercetin release was observed at neutral pH over four days. Critically, release was slower in acidic conditions, mimicking tumor microenvironments, suggesting potential for modulated drug release. These findings highlight the potential of niosome-encapsulated quercetin for thyroid cancer therapy. The nanosized vesicles, spherical morphology, pH-sensitive release, and stability suggest improved drug delivery and enhanced quercetin’s anti-cancer activity. This targeted approach may potentially reduce the need for total thyroidectomy. Further in vitro and in vivo studies are warranted to evaluate efficacy and safety in preclinical thyroid cancer models, specifically investigating the potential to minimize surgical intervention. This research contributes to improved, less invasive thyroid cancer treatments.